Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Receivables (2017 - 2023)

VYNE Therapeutics' Receivables history spans 7 years, with the latest figure at $250000.0 for Q3 2023.

  • For Q3 2023, Receivables fell 46.92% year-over-year to $250000.0; the TTM value through Sep 2023 reached $250000.0, down 46.92%, while the annual FY2022 figure was $173000.0, 98.68% down from the prior year.
  • Receivables reached $250000.0 in Q3 2023 per VYNE's latest filing, up from $234000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $21.6 million in Q4 2020 to a low of $105000.0 in Q1 2023.
  • Average Receivables over 5 years is $7.9 million, with a median of $4.4 million recorded in 2020.
  • Peak YoY movement for Receivables: soared 15914.07% in 2020, then crashed 98.68% in 2022.
  • A 5-year view of Receivables shows it stood at $135000.0 in 2019, then skyrocketed by 15914.07% to $21.6 million in 2020, then plummeted by 39.48% to $13.1 million in 2021, then plummeted by 98.68% to $173000.0 in 2022, then soared by 44.51% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for VYNE's Receivables are $250000.0 (Q3 2023), $234000.0 (Q2 2023), and $105000.0 (Q1 2023).